Related Experiment Video
Updated: Jul 9, 2025
A 3D Organotypic Melanoma Spheroid Skin Model
Published on: May 18, 2018
CAR NK Cell Therapy for the Treatment of Metastatic Melanoma: Potential & Prospects
Winston Hibler1, Glenn Merlino1, Yanlin Yu1
1Laboratory of Cancer Biology and Genetics, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
Abstract:
Melanoma is among the most lethal forms of cancer, accounting for 80% of deaths despite comprising just 5% of skin cancer cases. Treatment options remain limited due to the genetic and epigenetic mechanisms associated with melanoma heterogeneity that underlie the rapid development of secondary drug resistance. For this reason, the development of novel treatments remains paramount to the improvement of patient outcomes. Although the advent of chimeric antigen receptor-expressing T (CAR-T) cell immunotherapies has led to many clinical successes for hematological malignancies, these treatments are limited in their utility by their immune-induced side effects and a high risk of systemic toxicities. CAR natural killer (CAR-NK) cell immunotherapies are a particularly promising alternative to CAR-T cell immunotherapies, as they offer a more favorable safety profile and have the capacity for fine-tuned cytotoxic activity. In this review, the discussion of the prospects and potential of CAR-NK cell immunotherapies touches upon the clinical contexts of melanoma, the immunobiology of NK cells, the immunosuppressive barriers preventing endogenous immune cells from eliminating tumors, and the structure and design of chimeric antigen receptors, then finishes with a series of proposed design innovations that could improve the efficacy CAR-NK cell immunotherapies in future studies.
Insights
Chimeric antigen receptor natural killer (CAR-NK) cell immunotherapies show promise for treating melanoma, offering a safer alternative to CAR-T cell therapies. This review explores CAR-NK potential, addressing melanoma
Area of Science:
- Immunology
- Oncology
- Biotechnology
Background:
- Melanoma is a lethal cancer with limited treatment options due to drug resistance.
- Chimeric antigen receptor T (CAR-T) cell therapy has limitations including side effects and toxicity.
- Chimeric antigen receptor natural killer (CAR-NK) cell therapy presents a safer alternative with tunable activity.
Purpose of the Study:
- To review the potential of CAR-NK cell immunotherapies for melanoma treatment.
- To discuss the challenges posed by melanoma's heterogeneity and drug resistance.
- To explore innovations in CAR-NK design for improved efficacy.
Main Methods:
- Review of existing literature on melanoma, NK cell immunobiology, and CAR technology.
- Analysis of immunosuppressive barriers in the tumor microenvironment.
- Discussion of CAR structure, design principles, and potential innovations.
Main Results:
- CAR-NK cells offer a potentially safer and more effective immunotherapy approach compared to CAR-T cells for melanoma.
- Understanding NK cell immunobiology and tumor immunosuppression is crucial for CAR-NK development.
- Proposed design innovations aim to enhance CAR-NK cell persistence and anti-tumor activity.
Conclusions:
- CAR-NK cell immunotherapy is a promising avenue for overcoming melanoma treatment resistance.
- Further research into CAR-NK design and application is warranted to improve patient outcomes.
- CAR-NK cell therapy holds significant potential as a next-generation cancer immunotherapy.
More Related Videos
11:08Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells
Published on: February 14, 2025
08:19Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo
Published on: July 20, 2019
Related Concept Videos
01:27Cytotoxic T Cells-mediated Immune Response
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
01:27Tumor Immunotherapy